NASDAQ · Biotechnology

Ultragenyx Pharmaceutical Inc. (RARE) Stock

$27.11 +0.78% NASDAQ: RARE Healthcare

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative treatments for rare and ultra-rare genetic conditions.

Valuation

MetricValue
Price$27.11
Market Cap$2.67B
P/E Ratio-4.40
P/B Ratio-11.47
P/S Ratio3.96
EPS (TTM)$-6.10
52-Week High$39.89
52-Week Low$18.29
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-414.17%
ROA-47.02%
ROCE-57.86%
Gross Margin-28.06%
Operating Margin-1.02%
Net Margin-91.03%
Debt/Equity-5.08
Current Ratio2.02

Annual Financials (USD)

Metric20212022202320242025
Revenue$351.0M$363.0M$434.0M$560.0M$673.0M
Operating Profit$-382.0M$-649.0M$-569.0M$-536.0M$-535.0M
Net Profit$-454.0M$-707.0M$-607.0M$-569.0M$-575.0M
EPS$-6.70$-10.12$-8.25$-6.29$-5.83
Op Margin-108.6%-178.6%-131.1%-95.7%-79.5%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$1.5B$1.5B$1.5B$1.5B$1.5B
Total Liabilities$600.0M$1.2B$1.2B$1.2B$1.6B
Cash$308.0M$133.0M$214.0M$174.0M$434.0M
Borrowings$42.0M$32.0M$43.0M$40.0M$1.3B

Latest News

Wedbush Raises Price Target on Ultragenyx Pharmaceutical to $30 From $26, Keeps Neutral Rating MT Newswires · Jul 13, 2026 Ultragenyx Releases 2025 Impact Report Emphasizing Commitment to Rare Disease Patients, Innovation, and Global Impact GlobeNewswire · Jul 8, 2026 IONS Completes Enrollment in Pivotal Cohort of Angelman Syndrome Study Zacks · Jul 7, 2026 RBC Capital Adjusts Ultragenyx Pharmaceutical Price Target to $40 From $35, Maintains Outperform Rating MT Newswires · Jul 7, 2026 Ultragenyx (RARE) Soars 5.2%: Is Further Upside Left in the Stock? Zacks · Jun 29, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-339.0M$-380.0M$-475.0M$-414.0M$-466.0M
Investing Cash Flow$-268.0M$-438.0M$121.0M$-25.0M$230.0M
Financing Cash Flow$40.0M$501.0M$8.0M$18.0M$0
Net Cash Flow$-417.0M$-172.0M$82.0M$-35.0M$253.0M
Free Cash Flow$-412.0M$-527.0M$-522.0M$-422.0M$-472.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.90
EV / EBITDA-7.30
FCF Yield-17.68%
Quick Ratio1.65
Interest Coverage-8.63
Return 1Y4.56%
Return 3Y-36.01%
Return 5Y-66.58%

Ownership

Insiders Held3.45%
Institutions Held101.90%
Institutions Float Held105.54%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPGAscentage Pharma Group International $20.18 +4.89% -9.87 $1.88B 0.00%
APGE $134.19 +0.06% -16.89 $8.30B 0.00%
CELC $92.49 +5.44% -91.68 $4.51B 0.00%
CGON $72.17 -1.84% -26.72 $6.37B 0.00%
CNTACentessa Pharmaceuticals plc $40.50 +0.00% -22.75 $6.27B 0.00%

About Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative treatments for rare and ultra-rare genetic conditions. Its operations span North America, Europe, and other international markets. The company's portfolio of marketed biologic products addresses several serious diseases. This includes Crysvita (burosumab), an antibody that targets fibroblast growth factor 23, used to treat X-linked hypophosphatemia and tumor-induced osteomalacia. Mepsevii offers enzyme replacement therapy for both pediatric and adult patients suffering from Mucopolysaccharidosis VII. Dojolvi is available for individuals with long-chain fatty acid oxidation disorders, while Evkeeza (evinacumab) provides a treatment option for homozygous familial hypercholesterolemia. Ultragenyx also boasts a robust pipeline of investigational therapies. Notable candidates include DTX401, an adeno-associated virus 8 (AAV8) gene therapy for glycogen storage disease type Ia, and DTX301, another AAV8 gene therapy aimed at ornithine transcarbamylase deficiency. Other promising developments feature UX143, a human monoclonal antibody for osteogenesis imperfecta; GTX-102, an antisense oligonucleotide designed for Angelman syndrome; UX701, targeting Wilson disease; and UX053, in development for glycogen storage disease type III. To advance its research and development efforts, Ultragenyx Pharmaceutical Inc. maintains strategic collaboration and licensing agreements with numerous partners, such as Kyowa Kirin Co., Ltd., Saint Louis University, REGENXBIO Inc., Bayer Healthcare LLC, GeneTx, Mereo, University of Pennsylvania, Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc., and Daiichi Sankyo Co., Ltd. The company was founded in 2010 and operates from its headquarters in Novato, California.

Ultragenyx Pharmaceutical Inc. (RARE) stock trades at $27.11 with a market capitalization of $2.67B. The stock is valued at a price-to-earnings (P/E) ratio of -4.40, price-to-book of -11.47, price-to-sales of 3.96. Over the past 52 weeks the stock has ranged between $18.29 and $39.89, and currently trades 32.0% below its 52-week high.

On profitability, Ultragenyx Pharmaceutical Inc. generates a return on equity (ROE) of -414.17%, return on capital employed of -57.86%, an operating margin of -1.02%, a net profit margin of -91.03%.

Official website: www.ultragenyx.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides